EOLS
Evolus, Inc. [EOLS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
EOLS Stock Summary
Top 10 Correlated Stocks
EOLS
In the News
EOLS Financial details
Company Rating
-
Market Cap
743.51M
Income
-61.69M
Revenue
201.39M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
273
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-9.54
Forward P/E
-
PEG
5.29
P/S
3.31
P/B
-31.03
P/C
-
P/FCF
-3.91
Quick Ratio
1.42
Current Ratio
1.9
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.09
EPS next Y
-
EPS next Q
-
EPS this Y
-18.8%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-19.48%
Revenue last 5Y
42.06%
Revenue Q/Q
23.67%
EPS Q/Q
-30%
-
-
-
-
SMA20
3.15%
SMA50
24.23%
SMA100
-15.82%
Inst Own
-
Inst Trans
-
ROA
-38%
ROE
28547%
ROC
-0.4%
Gross Margin
70%
Oper. Margin
-26%
Profit Margin
-34%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.07-15.433
52W High
-9.47%
52W Low
+94%
RSI
47.02
Rel Volume
1.11
Avg Volume
670.92K
Volume
745.53K
Perf Week
-5.17%
Perf Month
-3.14%
Perf Quarter
-17.5%
Perf Half Y
-7.68%
-
-
-
-
Beta
1.45
-
-
Volatility
0.38%, 0.57%
Prev Close
0.59%
Price
13.58
Change
-1.09%
Company Profile
- Volume Average 670.92K
- Market Capitalization 743.51M
- Employee 273
- CEO Mr. David Moatazedi
- Headquarters Newport Beach,CA,US
- IPO Date 2018-02-08
-
Website
https://www.evolus.com 
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
